Welcome to our dedicated page for Camping World SEC filings (Ticker: CWH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Camping World Holdings Inc. filings are more than routine paperwork—they map the seasonal ebb and flow of RV sales and the recurring revenue of the Good Sam Club. Whether you’re tracking inventory swings or roadside-assistance margins, every line of the 10-K matters. Yet dissecting hundreds of pages—or refreshing EDGAR for insider trades—consumes valuable time.
That’s why Stock Titan pairs real-time feeds with AI-powered summaries. You’ll see Camping World Holdings insider trading Form 4 transactions the moment they post, plus plain-English context. Need the latest Camping World Holdings quarterly earnings report 10-Q filing? We not only surface it, we explain how retail gross profit compares to service-plan income. Our dashboard covers every form: 8-Ks for dealership acquisitions, proxies for executive pay, and registration statements when new equity is issued.
Use cases are straightforward: monitor Camping World Holdings Form 4 insider transactions real-time ahead of earnings; compare segment margins with our Camping World Holdings earnings report filing analysis; or dive into compensation details via the Camping World Holdings proxy statement executive compensation. For long-view diligence, consult the Camping World Holdings annual report 10-K simplified; for sudden news, rely on Camping World Holdings 8-K material events explained. Still unsure? Our guided walkthrough, understanding Camping World Holdings SEC documents with AI, shows where to locate warranty-reserve changes and capital-expenditure plans. In short, we transform dense disclosures into actionable insight so you can decide faster—without missing a single Camping World Holdings SEC filings explained simply.
Camping World Holdings (CWH) Q2 2025 10-Q key takeaways
- Revenue rose 9.4% YoY to $1.98 bn; six-month sales up 6.9% to $3.39 bn.
- Profitability improved: gross profit +8% to $592 m; operating income +37% to $130 m. Operating margin expanded 130 bp to 6.6%.
- Net income attributable to CWH advanced to $30.2 m (EPS $0.48) from $9.8 m (EPS $0.22). Six-month EPS turned positive at $0.29 vs. –$0.28.
- Segment drivers: New-vehicle revenue +8.0%, Used-vehicle +19.0%, F&I +12.4%. Good Sam Services grew 3.2%.
- Expense trends: SG&A up 4.2% to $437 m; combined interest expense fell 19% to $51.8 m, supporting bottom-line growth.
- Balance sheet: cash declined to $118 m (–43% YTD) as inventories expanded $239 m and floor-plan notes rose $118 m. Long-term debt steady at $1.48 bn; total leverage 4.7 × equity.
- Cash flow pressure: YTD operating cash outflow of $44.6 m (vs. +$84.3 m LY) driven by working-capital build; investing cash outflow $180 m for capex & acquisitions.
- Shareholder returns: quarterly dividend maintained at $0.125/sh (paid $15.7 m YTD); no share repurchases apart from tax-withholding on RSUs.
- Other items: immaterial tax-asset restatement increased deferred tax asset by $43.8 m and APIC by $33.4 m.
Overall, stronger sales and cost control lifted earnings, but negative operating cash flow and higher inventory/floor-plan debt warrant monitoring.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has filed Post-Effective Amendment No. 1 to four previously effective Form S-8 registration statements. The company is deregistering all unsold shares that had been reserved for issuance under its 2018, 2019 and 2023 equity compensation and ESPP plans. The action follows shareholder approval on 29 Jul 2025 of both (1) an Asset Purchase Agreement with Gilead Sciences covering what may be substantially all of HOOKIPA’s assets and (2) a Plan of Dissolution. As the company now intends to liquidate and dissolve, it is terminating any further offerings under the affected registration statements and removing from registration the remaining shares (no reverse-split adjustment applied in counts).
The filing contains no financial results, but it confirms the end of HOOKIPA’s equity incentive programs and signals that the company will wind down operations once the asset sale closes and dissolution begins. There is no impact on outstanding shares already issued; the amendment solely affects unsold, unissued shares registered for future employee grants. Management states the filing satisfies the undertaking in Part II of each S-8 to remove such securities upon termination of the offerings.
DexCom, Inc. (DXCM) Form 144 filing discloses a proposed sale of 1,466 common shares by shareholder Sadie Stern through Morgan Stanley Smith Barney. The shares, valued at $130,459, are expected to be sold on or about 28 Jul 2025 on the NASDAQ. They represent roughly 0.0004 % of DexCom’s 392.1 million shares outstanding, implying minimal market impact.
The shares were acquired as restricted stock on 19 Nov 2023. In the last three months, the same holder completed four sales totaling 7,650 shares for $651,016 in gross proceeds, indicating an ongoing liquidation pattern. No other insiders or financial metrics are disclosed.
The filer affirms awareness of no undisclosed adverse information and notes potential reliance on a Rule 10b5-1 trading plan. Aside from insider-sale data, the filing contains no operational or earnings updates.